The diagnostic value of serum 25-Hydroxyvitamin D, MIS and Insulin-like Growth Factor 1 for polycystic ovary syndrome (PCOS)
Serum 25-Hydroxyvitamin D, MIS and Insulin-like Growth Factor 1 for polycystic ovary syndrome (PCOS)
Abstract
Objective To investigate blood levels and the importance of Müllerian Inhibiting Substance (MIS), insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), and 25-hydroxyvitamin D [25(OH)D] in patients with polycystic ovarian syndrome (PCOS).
Methods The observation group consisted of 212 PCOS patients who received treatment at this institution between May 2022 and May 2024, while the control group consisted of 212 healthy women who were examined physically at same hospital within the same time frame. The two groups' general information, serum 25(OH)D, MIS, IGF-1, and IGFBP-3 levels, as well as their sex hormones and glucose metabolism markers, were compared. PCOS patients were divided into the IR group and the non-IR group according to whether insulin resistance (IR) occurred. The two groups' levels of serum 25(OH)D, MIS, IGF-1, and IGFBP-3 were compared. The study examined the associations among the four markers and the homeostasis model of insulin resistance index (HOMA-IR), as well as their supplementary diagnostic utility for PCOS.
Results The level of 25(OH)D in the observation group was lower than that in the control group (P<0.05). Total testosterone (TT), luteinizing hormone (LH), estradiol (E2), fasting insulin (FINS), fasting blood glucose (FBG), serum MIS, IGF-1, IGFBP-3, HOMA-IR, and the average body mass index were all greater in the observation group than in the control group (P<0.05). The IR group's 25(OH)D level was lower than the non-IR group's (P<0.05). Serum MIS, IGF-1, and IGFBP-3 levels were higher in the IR group than in the non-IR group (P<0.05). The levels of serum MIS, IGF-1 and IGFBP-3 in the observation group were positively correlated with HOMA-IR (r=0.659, 0.586, 0.565, P<0.05), and 25(OH)D was negatively correlated with HOMA-IR (r=-0.548, P<0.05). The combined auxiliary diagnosis of PCOS by serum 25(OH)D, MIS, IGF-1, and IGFBP-3 had an area under the curve of 0.963, according to the results of receiver operating characteristic curve analysis, which was greater than that of the single detection of each index (0.819, 0.864, 0.814, 0.799).
Conclusion MIS, IGF-1, IGFBP-3, and serum 25(OH)D levels are associated with the development and occurrence of PCOS. The combined detection of these four indicators has high auxiliary diagnostic value for PCOS and is conducive to clinical prevention and treatment.
References
2.Zhao J, Fu S, Chen Q. Serum 25-hydroxyvitamin D is associated with homocysteine in infertile patients with polycystic ovary syndrome (PCOS). Ginekol Pol. 2024;95(10):763-769. doi: 10.5603/gpl.94879. Epub 2024 Mar 20. PMID: 38506476.
3.Eickman K, Maxwell R, McGinnis LK, Stanczyk F, Legro R, Lindheim SR. Total and bioavailable 25-hydroxyvitamin D is not associated with improved sexual dysfunction following vitamin D supplementation in women with polycystic ovarian syndrome: a pilot study. J Sex Med. 2024 Feb 27;21(3):240-247. doi: 10.1093/jsxmed/qdad176. PMID: 38303661; PMCID: PMC10906494.
4.Fu Y, Wang YH, Wang L, Huang MR. Correlation between follicular fluid of 25-hydroxyvitamin D level and endocrine function, ovarian function and insulin resistance in women with polycystic ovary syndrome. J Physiol Pharmacol. 2025 Jun;76(3). doi: 10.26402/jpp.2025.3.07. Epub 2025 Jul 16. PMID: 40698789.
5.Li H, Zhang Y, Liu C, Zhang Y, Yang H, Fu S, Lv H. Association of Insulin-Like Growth Factor-1 With Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis. Endocr Pract. 2023 May;29(5):388-397. doi: 10.1016/j.eprac.2022.12.004. Epub 2022 Dec 11. PMID: 36516939.
6.Fu Y, Sun Q, Zhu K, Hu C. Elevated Insulin-Like Growth Factor-1-Induced Female Rats Perpetuate the Polycystic Ovary Syndrome Phenotype: Pathological Mechanism of Insulin-Like Growth Factor-1 in Polycystic Ovary Syndrome. Gynecol Obstet Invest. 2023;88(3):143-149. doi: 10.1159/000529354. Epub 2023 Feb 2. PMID: 36731447.
7.Farhadi-Azar M, Ghahremani M, Mahboobifard F, Noroozzadeh M, Yaghmaei P, Tehrani FR. Effects of Rosa damascena on reproductive improvement, metabolic parameters, liver function and insulin-like growth factor-1 gene expression in estradiol valerate induced polycystic ovarian syndrome in Wistar rats. Biomed J. 2023 Jun;46(3):100538. doi: 10.1016/j.bj.2022.05.003. Epub 2022 May 21. PMID: 35605922; PMCID: PMC10209690.
8.Atiomo W, Alqutami F, Albasha S, Hachim M. Deciphering the Role of Insulin-Like Growth Factor 1 in Endometrial Cancer in Patients With Polycystic Ovary Syndrome: Protocol for a Methodological Approach Using Cell Culture Experiments. JMIR Res Protoc. 2023 Nov 21;12:e48127. doi: 10.2196/48127. PMID: 37988160; PMCID: PMC10698646.
9.Wang Y, Li R, Sun B, Song W, Zhao X, Hu Y. Relationship of Serum Nesfatin-1 and Insulin-Like Growth Factor-1 Levels with Adverse Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome. J Coll Physicians Surg Pak. 2024 Oct;34(10):1167-1171. doi: 10.29271/jcpsp.2024.10.1167. PMID: 39410683.
10.Lu J, Xuan F, Chen A, Jin R, Zhou W, Ye Y, Ren Y. MicroRNA-646 inhibits the proliferation of ovarian granulosa cells via insulin-like growth factor 1 (IGF-1) in polycystic ovarian syndrome (PCOS). Endokrynol Pol. 2023;74(3):305-314. doi: 10.5603/EP.a2023.0020. Epub 2023 May 8. PMID: 37155307.
11.Amin AF, Abd el-Aal DE, Darwish AM, Meki AR. Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr;79(4):938-41. doi:10.1016/s0015-0282(0204849-5). PMID: 12749434. Fertil Steril. 2024 Aug;122(2):394. doi: 10.1016/j.fertnstert.2024.05.151. PMID: 39069373.
12.Wu L, Li X, Yan J. Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol. 2024 Jul;45:101995. doi: 10.1016/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241.
13.Stańczak NA, Grywalska E, Dudzińska E. The latest reports and treatment methods on polycystic ovary syndrome. Ann Med. 2024 Dec;56(1):2357737. doi: 10.1080/07853890.2024.2357737. Epub 2024 Jul 4. PMID: 38965663; PMCID: PMC11229724.
14.Di Lorenzo M, Cacciapuoti N, Lonardo MS, Nasti G, Gautiero C, Belfiore A, Guida B, Chiurazzi M. Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review. Curr Nutr Rep. 2023 Sep;12(3):527-544. doi: 10.1007/s13668-023-00479-8. Epub 2023 May 22. PMID: 37213054; PMCID: PMC10444658.
15.Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023 Jan 11;16(1):9. doi: 10.1186/s13048-022-01091-0. PMID: 36631836; PMCID: PMC9832677.
16.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
17.Su P, Chen C, Sun Y. Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. J Ovarian Res. 2025 Feb 20;18(1):34. doi: 10.1186/s13048-025-01621-6. PMID: 39980043; PMCID: PMC11841159.
18.Calcaterra V, Rossi V, Massini G, Casini F, Zuccotti G, Fabiano V. Probiotics and Polycystic Ovary Syndrome: A Perspective for Management in Adolescents with Obesity. Nutrients. 2023 Jul 14;15(14):3144. doi: 10.3390/nu15143144. PMID: 37513562; PMCID: PMC10384396.
19.Chang KJ, Chen JH, Chen KH. The Pathophysiological Mechanism and Clinical Treatment of Polycystic Ovary Syndrome: A Molecular and Cellular Review of the Literature. Int J Mol Sci. 2024 Aug 20;25(16):9037. doi: 10.3390/ijms25169037. PMID: 39201722; PMCID: PMC11354688.
20.Peña AS, Witchel SF, Boivin J, Burgert TS, Ee C, Hoeger KM, Lujan ME, Mousa A, Oberfield S, Tay CT, Teede H. International evidence-based recommendations for polycystic ovary syndrome in adolescents. BMC Med. 2025 Mar 11;23(1):151. doi: 10.1186/s12916-025-03901-w. PMID: 40069730; PMCID: PMC11899933.
21.Mimouni NEH, Giacobini P. Polycystic ovary syndrome (PCOS): progress toward a better understanding and treatment of the syndrome. C R Biol. 2024 Apr 19;347:19-25. doi: 10.5802/crbiol.147. PMID: 38639155.
22.Simon SL, Phimphasone-Brady P, McKenney KM, Gulley LD, Bonny AE, Moore JM, Torres-Zegarra C, Cree MG. Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood. Lancet Child Adolesc Health. 2024 Jun;8(6):443-455. doi: 10.1016/S2352-4642(24)00019-1. Epub 2024 Mar 27. PMID: 38552655; PMCID: PMC11837223.
23.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
24.Almhmoud H, Alatassi L, Baddoura M, Sandouk J, Alkayali MZ, Najjar H, Zaino B. Polycystic ovary syndrome and its multidimensional impacts on women's mental health: A narrative review. Medicine (Baltimore). 2024 Jun 21;103(25):e38647. doi: 10.1097/MD.0000000000038647. PMID: 38905372; PMCID: PMC11191963.
25.Stefanaki K, Karagiannakis DS, Peppa M, Vryonidou A, Kalantaridou S, Goulis DG, Psaltopoulou T, Paschou SA. Food Cravings and Obesity in Women with Polycystic Ovary Syndrome: Pathophysiological and Therapeutic Considerations. Nutrients. 2024 Apr 3;16(7):1049. doi: 10.3390/nu16071049. PMID: 38613082; PMCID: PMC11013286.
26.Cichocka E, Maj-Podsiadło A, Gumprecht J. Polycystic ovary syndrome and type 1 diabetes - the current state of knowledge. Endokrynol Pol. 2024;75(5):479-485. doi: 10.5603/ep.101392. Epub 2024 Oct 8. PMID: 39376174.
27.Colombo GE, Pirotta S, Sabag A. Diet and Exercise in the Management of Polycystic Ovary Syndrome: Practical Considerations for Person-Centered Care. Semin Reprod Med. 2023 Mar;41(1-02):26-36. doi: 10.1055/s-0043-1777116. Epub 2023 Dec 1. PMID: 38040023.
28.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
29.Colombo GE, Pirotta S, Sabag A. Diet and Exercise in the Management of Polycystic Ovary Syndrome: Practical Considerations for Person-Centered Care. Semin Reprod Med. 2023 Mar;41(1-02):26-36. doi: 10.1055/s-0043-1777116. Epub 2023 Dec 1. PMID: 38040023.
30.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
31.Yu O, Christ JP, Schulze-Rath R, Covey J, Kelley A, Grafton J, Cronkite D, Holden E, Hilpert J, Sacher F, Micks E, Reed SD. Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: a United States population-based study from 2006 to 2019. Am J Obstet Gynecol. 2023 Jul;229(1):39.e1-39.e12. doi: 10.1016/j.ajog.2023.04.010. Epub 2023 Apr 14. PMID: 37061077.
32.Tay CT, Garrad R, Mousa A, Bahri M, Joham A, Teede H. Polycystic ovary syndrome (PCOS): international collaboration to translate evidence and guide future research. J Endocrinol. 2023 Apr 28;257(3):e220232. doi: 10.1530/JOE-22-0232. PMID: 36946556.
33.Han Y, Wu H, Sun S, Zhao R, Deng Y, Zeng S, Chen J. Effect of High Fat Diet on Disease Development of Polycystic Ovary Syndrome and Lifestyle Intervention Strategies. Nutrients. 2023 May 8;15(9):2230. doi: 10.3390/nu15092230. PMID: 37432488; PMCID: PMC10180647.
34.Xiaomei Z, Xiaoyan F. Effect of cinnamon as a Chinese herbal medicine on markers of cardiovascular risk in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2024 Sep;300:253-261. doi: 10.1016/j.ejogrb.2024.07.032. Epub 2024 Jul 18. PMID: 39053085.
35.Gautam R, Maan P, Patel AK, Vasudevan S, Arora T. Unveiling the complex interplay between gut microbiota and polycystic ovary syndrome: A narrative review. Clin Nutr. 2024 Dec;43(12):199-208. doi: 10.1016/j.clnu.2024.10.028. Epub 2024 Oct 22. PMID: 39481287.
Copyright (c) 2025 Shaomeng Sun, Jianrui Zheng, Ziying Xie
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.